Acetyl L-Carnitine

non-nutrient_non-botanical
View products

Acetyl L-Carnitine (ALCAR) is an amino acid derivative synthesized in the body from lysine and methionine. Its acetyl group allows it to cross the blood-brain barrier more readily than L-carnitine. It transports fatty acids into mitochondria, where they are oxidized for energy. It supports neuroprotective processes and cognitive health. It contributes to the production of acetylcholine, a neurotransmitter involved in memory and learning. It also acts as an antioxidant to help protect brain cells from oxidative stress. ALCAR is used for its potential to support cognitive function, mood, and physical performance. Researchers also study its benefits in conditions involving nerve pain, fatigue, and age-related cognitive decline.

Natural sources
Red meat (especially beef)Fish (e.g., cod, salmon)PoultryDairy productsAvocadosTempeh

No public comparison lists found.

Optimal Dosage
Minimum500 mg
Maximum1500 mg
Safety & Toxicity
Toxicity Threshold4000 mg
Toxicity EffectRestlessness, gastrointestinal discomfort
4 safety notes
  • Pregnant or breastfeeding individuals should consult a healthcare professional before use.
  • Individuals with a history of seizures should use with caution and under medical supervision, as ALCAR might potentially lower the seizure threshold in some cases.
  • Those with hypothyroidism should consult a doctor, as L-carnitine (and by extension ALCAR) may inhibit thyroid hormone activity.
  • Individuals with kidney disease should use with caution and medical guidance.
Goals
Cognitive Support
Cognitive Support
Impact
High effect
Typical dose:500–1500 mg

This form of L-Carnitine can cross the blood-brain barrier, where it helps transport fatty acids into mitochondria to be burned for energy. This process supports mental energy, reduces mental fatigue, and may improve focus and processing speed, particularly in aging individuals.

Focuses on
Memory PerformanceMental EnergyAttention and FocusProcessing SpeedCognitive Health in Aging
Most relevant for
Older adults facing age-related mental fatigue or individuals seeking to support cognitive health during early-stage memory decline.

Potential benefits

  • Support for Age-Related Memory.Trials in older adults with fatigue or pre-frailty show improvements in scores on memory and attention assessments.
  • Reduction in Mental Fatigue.Clinical studies suggest it may help reduce mental fatigue and improve concentration in individuals facing metabolic stress or aging.
  • Slowing Cognitive Decline.Unconfirmed. Some evidence suggests a slower rate of decline in early-stage cognitive impairment, though this effect has not been consistently proven in larger trials.

Limitations

  • Mixed Results in Dementia.Several large studies failed to show a meaningful benefit for cognitive or functional outcomes in patients with Alzheimer’s disease.
  • Lack of Data for Healthy Adults.There is currently no established evidence that this ingredient improves memory or cognitive performance in young, healthy populations.
  • Context-Dependent Benefits.Significant cognitive improvements are often linked to specific clinical conditions, such as liver-related brain dysfunction, and may not generalize to the general public.
Things to consider

Gastrointestinal side effects, including nausea and vomiting, have been reported in some clinical trials.

Study evidence

20 studies

Acetyl L-Carnitine has shown cognitive benefits in some people with liver-related brain dysfunction and in selected older populations, but results in Alzheimer’s disease are inconsistent. The available research does not establish a reliable memory or attention benefit for generally healthy adults.

View goal
Energy
Energy
Impact
High effect
Typical dose:500–2500 mg

By facilitating fat metabolism, Acetyl L-Carnitine (ALCAR) enhances energy production. Its acetyl group contributes to the production of acetylcholine, a key neurotransmitter for cognitive function, making it effective for reducing mental fatigue and brain fog.

Focuses on
Mental fatigue reductionPhysical fatigue reductionDaily activity levelsMitochondrial fuel transportIllness-related fatigue
Most relevant for
Individuals managing fatigue related to chronic health conditions, particularly liver disease or intensive medical treatments.

Potential benefits

  • Fatigue reduction in illness.Evidence shows ALCAR can lower mental and physical fatigue scores in patients with liver disease and those receiving intensive antiviral treatments.
  • Improved daily functioning.Clinical studies suggest supplementation may increase physical activity levels and improve scores on performance scales in medically fatigued populations.
  • Everyday energy enhancement.Unconfirmed. While ALCAR aids cellular energy metabolism, there is no direct evidence showing it improves alertness or reduces tiredness in healthy adults.

Limitations

  • Limited evidence for healthy adults.Research is heavily focused on clinical populations, leaving its efficacy for general energy needs in the broader public unproven.
  • Mixed findings for MS.Despite some positive trials, systematic reviews indicate that evidence for treating multiple sclerosis-related fatigue is currently insufficient.
  • Condition-specific outcomes.The benefits for fatigue vary significantly by health condition, with mixed or inconclusive results in areas like fibromyalgia and cancer.

Study evidence

19 studies

Acetyl L-Carnitine may reduce fatigue in some people with liver disease or treatment-related fatigue, but results vary by condition. The available research does not establish that it reliably boosts everyday energy in otherwise healthy people.

View goal
Mental Focus
Mental Focus
Impact
High effect
Typical dose:500–2000 mg

This acetylated form of L-Carnitine can cross the blood-brain barrier, where it helps transport fatty acids into mitochondria for energy production. This enhances mental energy and has been shown to combat age-related cognitive decline and mental fatigue.

Focuses on
Selective attentionMental energyInformation processingCognitive speedFatigue reduction
Most relevant for
Older adults with mild cognitive changes or individuals experiencing condition-related mental fatigue.

Potential benefits

  • Attention in Older Adults.Clinical trials demonstrate that long-term use can improve selective attention and performance on psychometric tests in older individuals with mild cognitive impairment.
  • Mental Fatigue Reduction.Research indicates it may help maintain daily functioning and reduce mental fatigue, particularly in individuals facing physical stress or specific medical treatments.
  • Everyday Concentration.Unconfirmed. While pilot studies suggest potential for improved learning speed in young adults, a reliable benefit for mental focus in healthy, high-functioning individuals is not yet proven.

Limitations

  • Population Specificity.The strongest evidence for improved focus is derived from studies on older adults with pre-existing cognitive impairment or Alzheimer's disease.
  • Inconsistent ADHD Results.Studies in children with ADHD did not show an overall improvement in primary attention measures, though specific subgroups may react differently.
  • Data Quality Concerns.Some meta-analyses regarding brain dysfunction have noted a high risk of bias and very low-quality evidence in the underlying research.
Things to consider

Cognitive benefits typically require consistent use for three to twelve months. Effectiveness for focus in healthy people remains uncertain due to limited controlled research.

Study evidence

7 studies

Acetyl L-Carnitine may support aspects of attention in people with cognitive impairment, but evidence for improving everyday mental focus in healthy people is limited. Results in children with attention difficulties are mixed, so benefits cannot be assumed across populations.

View goal
Metabolism Boost
Metabolism Boost
Impact
High effect
Typical dose:500–2000 mg

Acetyl L-Carnitine (ALCAR) is a highly bioavailable form of carnitine. It acts as a shuttle, moving long-chain fatty acids across the mitochondrial membrane where they can be oxidized ('burned') for ATP production. This is particularly beneficial during periods of calorie restriction or exercise.

Focuses on
Mitochondrial fatty acid transportNutrient absorptionEnergy metabolism support
Most relevant for
Healthy adults seeking to support metabolic pathways, though clinical evidence for an actual increase in metabolic rate is currently lacking.

Potential benefits

  • Theoretical Energy Support.Unconfirmed. Acetyl L-Carnitine is involved in transporting long-chain fatty acids into mitochondria for energy production, but research has not confirmed that this results in a measurable metabolism boost or increased calorie burning.

Limitations

  • Low Bioavailability.Oral acetylcarnitine has very low intestinal absorption compared to standard carnitine, with much of the supplement being rapidly excreted or converted.
  • Lack of Clinical Efficacy.Research in healthy volunteers does not show that supplementation increases energy use or provides a functional boost to metabolism.
Things to consider

Supplementation can lead to high production of TMAO, a metabolite that has been associated with potential adverse health outcomes in clinical studies.

Study evidence

1 study

The supplied research does not establish that Acetyl L-Carnitine boosts metabolic rate or energy use. It instead shows limited absorption and substantial production of a metabolite associated with health concerns, without directly demonstrating clinical harm.

View goal
Productivity Boost
Productivity Boost
Impact
High effect
Typical dose:500–2000 mg

Acetyl L-Carnitine (ALCAR) crosses the blood-brain barrier to assist in mitochondrial energy production and provides acetyl groups for synthesizing acetylcholine, a neurotransmitter critical for focus, memory, and cognitive speed. It's particularly effective at reducing mental fatigue.

Focuses on
Work performance lossMental fatigue reductionDaily activity maintenancePresenteeism reductionPhysical fatigue reduction
Most relevant for
Individuals experiencing work performance issues or mental fatigue specifically related to chronic health conditions or medical treatments.

Potential benefits

  • Treatment-Related Productivity.In a clinical study of patients receiving intensive medical treatment, supplementation helped reduce the loss of work productivity and improved daily activity levels.
  • Fatigue Mitigation.Evidence suggests it can significantly decrease mental and physical fatigue, which may indirectly support work performance in those facing health-related exhaustion.
  • Healthy Population Boost.Unconfirmed. Evidence for enhancing productivity or cognitive output in healthy workers is currently unproven, as research focuses on restoring function in fatigued populations.

Limitations

  • Narrow Clinical Evidence.Studies are primarily limited to individuals with chronic hepatitis C undergoing interferon therapy; results may not apply to the general population.
  • Restorative vs Enhancing.Data supports reducing performance loss rather than providing an extra boost to baseline productivity in individuals who are not already fatigued.
Things to consider

The primary study used a high dosage of 2 grams twice daily. Individuals with underlying health conditions should consult a professional, as benefits were observed in a specific medical context.

Study evidence

1 study

Acetyl L-Carnitine may help preserve work productivity and reduce fatigue in people receiving certain hepatitis C treatments. The available evidence concerns treatment-related difficulties and does not establish a productivity boost for healthy people or workers in general.

View goal
Productivity Boost
Productivity Boost
Impact
High effect
Typical dose:500–2000 mg

Acetyl L-Carnitine (ALCAR) crosses the blood-brain barrier to assist in mitochondrial energy production and provides acetyl groups for synthesizing acetylcholine, a neurotransmitter critical for focus, memory, and cognitive speed. It's particularly effective at reducing mental fatigue.

Focuses on
Mental fatigue reductionWork performance preservationDecreased presenteeismDaily activity support
Most relevant for
Individuals experiencing work performance loss or presenteeism related to chronic fatigue or specific medical treatments.

Potential benefits

  • Mental Fatigue Reduction.Clinical evidence indicates it can decrease mental fatigue, which may help maintain the focus required for productive work.
  • Work Performance Preservation.Research shows it helps individuals maintain their ability to work and reduces daily activity impairment when facing health-related fatigue.
  • General Productivity Boost.Unconfirmed. While ALCAR helps preserve function in clinical settings, its ability to boost productivity in healthy individuals is unproven.

Limitations

  • Narrow Clinical Context.Supportive evidence is currently limited to patients undergoing interferon therapy for hepatitis C; effects on general workplace productivity are unknown.
  • High Dose Requirements.The observed productivity benefits were associated with a high clinical dose of 4g per day administered over 12 months.
Things to consider

Studies focused on patients specifically undergoing Pegylated-Interferon-alpha 2b and Ribavirin treatment.

Study evidence

1 study

Acetyl L-Carnitine may help preserve work productivity and reduce fatigue in people receiving certain hepatitis C treatments. The available evidence concerns treatment-related difficulties and does not establish a productivity boost for healthy people or workers in general.

View goal
Showing 6 of 9 goals

Studies

Research connections will load here.
Sources

Up to five highest-ranked published examples per goal. Study counts and charts include all published studies for the connection.

  1. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.
    Malaguarnera M; Gargante MP; Cristaldi E; Vacante M; Risino C; Cammalleri L; Pennisi G; Rampello L · Digestive diseases and sciences · 2008
    Randomized trial125 participantsCognitive SupportBrain Health
  2. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
    Torrioli MG; Vernacotola S; Peruzzi L; Tabolacci E; Mila M; Militerni R; Musumeci S; Ramos FJ; Frontera M; Sorge G; Marzullo E; Romeo G; Vallee L; Veneselli E; Cocchi E; Garbarino E; Moscato U; Chiurazzi P; D'Iddio S; Calvani M; Neri G · American journal of medical genetics. Part A · 2008
    Randomized trial63 participantsCognitive Support
  3. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.
    Malaguarnera M; Vacante M; Motta M; Giordano M; Malaguarnera G; Bella R; Nunnari G; Rampello L; Pennisi G · Metabolic brain disease · 2012
    Randomized trial61 participantsCognitive SupportBrain Health
  4. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M · Neurology · 1991
    Randomized trial130 participantsCognitive SupportBrain Health
  5. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
    Malaguarnera M; Gargante MP; Cristaldi E; Colonna V; Messano M; Koverech A; Neri S; Vacante M; Cammalleri L; Motta M · Archives of gerontology and geriatrics · 2008
    Randomized trial96 participantsCognitive Support
  6. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
    Malaguarnera M; Vacante M; Giordano M; Pennisi G; Bella R; Rampello L; Malaguarnera M; Li Volti G; Galvano F · The American journal of clinical nutrition · 2011
    Randomized trial121 participantsEnergy
  7. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
    Malaguarnera M; Vacante M; Bertino G; Neri S; Malaguarnera M; Gargante MP; Motta M; Lupo L; Chisari G; Bruno CM; Pennisi G; Bella R · Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012
    Randomized trial60 participantsEnergy
  8. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy.
    Malaguarnera M; Bella R; Vacante M; Giordano M; Malaguarnera G; Gargante MP; Motta M; Mistretta A; Rampello L; Pennisi G · Scandinavian journal of gastroenterology · 2011
    Randomized trial67 participantsEnergy
  9. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.
    Sun Y; Shu Y; Liu B; Liu P; Wu C; Zheng R; Zhang X; Zhuang Z; Deng Y; Zheng L; Xu Q; Jiang B; Ouyang X; Gao J; Xu N; Li X; Jiang S; Liang C; Yao Y · Experimental and therapeutic medicine · 2020
    Randomized trial239 participantsEnergy
  10. Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
    Kumar R; Nuñez NA; Joshi N; Joseph B; Verde A; Seshadri A; Cuellar Barboza AB; Prokop LJ; Medeiros GC; Singh B · Bipolar disorders · 2024
    Systematic reviewEnergy
  11. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U · International journal of clinical pharmacology research · 1990
    Randomized trial60 participantsMental FocusBrain Health
  12. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.
    Malaguarnera G; Pennisi M; Gagliano C; Vacante M; Malaguarnera M; Salomone S; Drago F; Bertino G; Caraci F; Nunnari G; Malaguarnera M · Hepatitis monthly · 2014
    Randomized trial62 participantsMental FocusProductivity Boost
  13. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration].
    Lino A; Boccia MM; Rusconi AC; Bellomonte L; Cocuroccia B · La Clinica terapeutica · 1992
    Non-randomized trial17 participantsMental Focus
  14. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial.
    Arnold LE; Amato A; Bozzolo H; Hollway J; Cook A; Ramadan Y; Crowl L; Zhang D; Thompson S; Testa G; Kliewer V; Wigal T; McBurnett K; Manos M · Journal of child and adolescent psychopharmacology · 2008
    Randomized trial112 participantsMental Focus
  15. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE · The Cochrane database of systematic reviews · 2019
    Meta-analysis398 participants5 studies pooledMental Focus
  16. Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism.
    Krims-Davis K; Ozola M; Razzivina V; Gukalova B; Konrade I; Dambrova M; Liepinsh E · Molecular nutrition & food research · 2025
    Randomized trialMetabolism Boost
  17. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.
    Malaguarnera G; Catania VE; Bertino G; Chisari LM; Castorina M; Bonfiglio C; Cauli O; Malaguarnera M · Current pharmaceutical design · 2022
    Randomized trial92 participantsAnti-Aging
  18. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome.
    Herrmann WM; Dietrich B; Hiersemenzel R · International journal of clinical pharmacology research · 1990
    Randomized trialBrain Health